血糖变异性与经皮冠脉介入术治疗患者预后相关性的研究进展

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (592 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Although percutaneous coronary intervention (PCI) is becoming more and more mature, the problem of blood glucose fluctuation associated with PCI is becoming more and more prominent. Blood glucose fluctuations, or glycemic variability, are unstable states between peaks and valleys in blood glucose values, including short-term and long-term glycemic variability. Glycemic variability is the result of the interaction of multiple factors, which is easy to accelerate the process of coronary artery disease in patients treated by PCI, resulting in stent restenosis. It is also an independent predictor of poor prognosis in patients treated with PCI, which can lead to an increased incidence of cardiovascular adverse events and mortality. In this paper, the relevant influencing factors of glycemic variability in patients treated with PCI, the relationship between glycemic variability and patient prognosis, and blood glucose management were reviewed in order to provide theoretical reference for future research in this area.

Key words： Coronary heart disease Percutaneous coronary intervention Glycemic variability Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Di1 TIAN Jinping 1
	2 LIU Yunyue1 WANG Mi1 WANG Jie1

Cite this article:

XU Di1 TIAN Jinping 1,2 LIU Yunyue1 WANG Mi1 WANG Jie1. Research progress on the relationship between glycemic variability and prognosis of patients undergoing percutaneous coronary intervention[J]. 中国医药导报, 2021, 18(27): 51-54.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I27/51

[1] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J].中国循环杂志，2020，35（9）：833-854.
[2] Ibanez B，James S，Agewall S，et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation：The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology（ESC）[J]. Eur Heart J，2018，39（2）：119-177.
[3] Su G，Mi SH，Tao H，et al. Impact of admission glycemic variability，glucose，and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction [J]. Diabetes Care，2013，36（4）：1026-1032.
[4] 中华医学会糖尿病学分会.中国持续葡萄糖监测临床应用指南（2017年版）[J].中华糖尿病杂志，2017，9（11）：667-675.
[5] 王亚昕，贺星星，马晓静，等.血糖、血压等变异度与糖尿病心血管并发症的研究进展[J].中华内科杂志，2020，59（12）：999-1002.
[6] Kuroda M，Shinke T，Sakaguchi K，et al. Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy：a prospective observational study [J]. JACC Cardiovasc Interv，2015， 8（6）：800-811.
[7] Kuroda M，Shinke T，Otake H，et al. Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography [J]. Cardiovasc Diabetol，2016，15：79.
[8] Murata M，Adachi H，Oshima S，et al. Glucose fluctuation and the resultant endothelial injury are correlated with pancreatic β cell dysfunction in patients with coronary artery disease [J]. Diabetes Res Clin Pract，2017，131：107-115.
[9] Gohbara M，Iwahashi N，Sato R，et al. Skeletal muscle mass is associated with glycemic variability in patients with ST-segment elevation myocardial infarction [J]. Heart Vessels，2021，36（7）：945-954.
[10] Tokue M，Iijima R，Imamura T，et al. Impact of glycemic variability in patients with ST-elevated myocardial infarction [J]. Int J Cardiol，2015，187：660-662.
[11] Paing AC，McMillan KA，Kirk AF，et al. Dose-response between frequency of interruption of sedentary time and fasting glucose，the dawn phenomenon and night-time glucose in Type 2 diabetes [J]. Diabet Med，2019，36（3）：376-382.
[12] 翟小方，李惠琴，苏晓飞，等.应用动态血糖监测评价甘精胰岛素治疗2型糖尿病患者血糖控制的研究[J].中国糖尿病杂志，2020，28（4）：272-275.
[13] 杨秀秀，苏工.血糖变异性对2型糖尿病合并急性冠状动脉综合征患者非罪犯病变快速进展的影响[J].中国介入心脏病学杂志，2018，26（11）：613-618.
[14] Yamamoto H，Shinke T，Otake H，et al. Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipid-lowering therapy [J]. J Diabetes Investig，2021，12（6）：1015-1024.
[15] Teraguchi I，Imanishi T，Ozaki Y，et al. Impact of glucose fluctuation and monocyte subsets on coronary plaque rupture [J]. Nutr Metab Cardiovasc Dis，2014，24（3）：309-314.
[16] Okada K，Hibi K，Gohbara M，et al. Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes [J]. Cardiovasc Diabetol，2015，14：111.
[17] Tsuchida K，Nakamura N，Soda S，et al. Relationship Between Glucose Fluctuations and ST-Segment Resolution in Patients With ST-Elevation Acute Myocardial Infarction [J]. Int Heart J，2017，58（3）：328-334.
[18] Nusca A，Tuccinardi D，Proscia C，et al. Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention [J]. Cardiovasc Diabetol，2019，18（1）：147.
[19] Benalia M，Zeller M，Mouhat B，et al. Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction [J]. Diabetes Metab，2019，45（5）：446-452.
[20] 成万钧，张建维，杨士伟，等.血糖变异性对行急诊冠状动脉介入术ST段抬高型心肌梗死患者短期预后的影响[J].中华实用诊断与治疗杂志，2016，30（1）：55-57.
[21] 柳梅，范学朋，张伟明，等.急性心肌梗死冠状动脉介入术围手术期血糖变异和预后的相关性分析[J].中国急救医学，2016，36（8）：696-699.
[22] Su G，Zhang T，Yang H，et al. Admission glycemic variability correlates with in-hospital outcomes in diabetic patients with non-ST segment elevation acute coronary syndrome undergoing percutaneous coronary intervention [J]. Anatol J Cardiol，2018，19（6）：368-373.
[23] 杨红霞，张涛，苏工，等.血糖变异性对非糖尿病急性ST段抬高型心肌梗死患者左心功能的影响[J].中国医药，2017，12（11）：1601-1604.
[24] Zuo P，Li Y，Zuo Z，et al. Glycemic variability as predictor of contrast-induced nephropathy in diabetic patients with acute myocardial infarction undergoing percutaneous coronary intervention [J]. Ann Transl Med，2020，8（22）：1505.
[25] Takahashi H，Iwahashi N，Kirigaya J，et al. Glycemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome [J]. Cardiovasc Diabetol，2018，17（1）：116.
[26] Gerbaud E，Darier R，Montaudon M，et al. Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients With Diabetes With Acute Coronary Syndrome [J]. Diabetes Care，2019，42（4）：674-681.
[27] Kang DO，Seo HS，Choi BG，et al. Absolute change in fasting plasma glucose over 12 months is associated with 2-year and 5-year major adverse cardiovascular events in patients with drug-eluting stent implants [J]. I Int J Cardiol，2015，179：146-152.
[28] Yang CD，Shen Y，Lu L，et al. Visit-to-visit HbA variability is associated with in-stent restenosis in patients with type 2 diabetes after percutaneous coronary intervention [J]. Cardiovasc Diabetol，2020，19（1）：133.
[29] Yang CD，Shen Y，Ding FH，et al. Visit-to-visit fasting plasma glucose variability is associated with left ventricular adverse remodeling in diabetic patients with STEMI [J]. Cardiovasc Diabetol，2020，19（1）：131.
[30] Kataoka Y，Hosoda K，Makino H，et al. The efficacy of glycemic control with continuous glucose monitoring on atheroma progression：rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus（OPTIMAL）[J]. Cardiovasc Diagn Ther，2019，9（5）：431-438.